Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Arun, S. Bayraktar, Diane Liu, A. Barrera, D. Atchley, L. Pusztai, J. Litton, V. Valero, F. Meric-Bernstam, G. Hortobagyi, C. Albarracin (2011)
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 28
J. Quinn, R. Kennedy, P. Mullan, Paula Gilmore, M. Carty, P. Johnston, D. Harkin (2003)
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.Cancer research, 63 19
G. Molyneux, F. Geyer, Fiona-Ann Magnay, Afshan Mccarthy, H. Kendrick, R. Natrajan, A. Mackay, A. Grigoriadis, A. Tutt, A. Ashworth, J. Reis-Filho, M. Smalley (2010)
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.Cell stem cell, 7 3
P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, Peter Mortimer, H. Swaisland, A. Lau, M. O’Connor, A. Ashworth, J. Carmichael, S. Kaye, J. Schellens, J. Bono (2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.The New England journal of medicine, 361 2
P. Tassone, P. Tassone, P. Tagliaferri, A. Perricelli, S. Blotta, B. Quaresima, Marialuisa Martelli, A. Goel, V. Barbieri, F. Costanzo, C. Boland, S. Venuta (2003)
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of Cancer, 88
Jacques Raphael, C. Mazouni, O. Caron, Malek Ferchiou, S. Delaloge (2014)
Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy?Medical Oncology, 31
S. Isakoff, B. Overmoyer, N. Tung, R. Gelman, V. Giranda, K. Bernhard, K. Habin, L. Ellisen, E. Winer, P. Goss (2010)
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.Journal of Clinical Oncology, 28
M. Kriege, C. Seynaeve, H. Meijers-Heijboer, J. Collée, M. Menke-Pluymers, C. Bartels, M. Tilanus-Linthorst, J. Blom, E. Huijskens, A. Jager, A. Ouweland, B. Geel, M. Hooning, C. Brekelmans, J. Klijn (2009)
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 23
Sharon Simchoni, E. Friedman, B. Kaufman, R. Gershoni-baruch, A. Orr-Urtreger, I. Kedar-Barnes, R. Shiri-Sverdlov, E. Dagan, S. Tsabari, M. Shohat, R. Catane, M. King, A. Lahad, E. Levy-Lahad (2006)
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.Proceedings of the National Academy of Sciences of the United States of America, 103 10
S. Bayraktar, S. Glück (2012)
Systemic therapy options in BRCA mutation-associated breast cancerBreast Cancer Research and Treatment, 135
P. Wysocki, Konstanty Korski, K. Lamperska, J. Zaluski, A. Mackiewicz (2008)
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.Medical science monitor : international medical journal of experimental and clinical research, 14 7
R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs, G. Micklem, R. Barfoot, R. Hamoudi, Sandeep Patel, Catherine Rices, P. Biggs, Yasmin Hashim, Amanda Smith, F. Connor, A. Arason, J. Gudmundsson, David Flcenec, D. Kelsell, D. Ford, P. Tonin, P. Tonin, D. Bishop, N. Spurr, B. Ponder, R. Eeles, J. Peto, P. Devilee, C. Cornelisse, H. Lynch, S. Narod, S. Narod, G. Lenoir, V. Egilsson, Rosa Barkadottir, D. Easton, D. Bentley, P. Futreal, A. Ashworth, M. Stratton (1995)
Identification of the breast cancer susceptibility gene BRCA2Nature, 378
Kevin Caestecker, G. Walle (2013)
The role of BRCA1 in DNA double-strand repair: past and present.Experimental cell research, 319 5
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, S. Narod, J. Lubiński, The Consortium (2008)
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancersBreast Cancer Research and Treatment, 108
K. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, H. Hirte, D. Huntsman, M. Clemons, B. Gilks, R. Yerushalmi, E. Macpherson, J. Carmichael, A. Oza (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.The Lancet. Oncology, 12 9
H. Holstege, S. Joosse, C. Oostrom, P. Nederlof, A. Vries, J. Jonkers (2009)
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.Cancer research, 69 8
J. Palacios, M. Frías, M. Castilla, M. López-García, J. Benítez (2008)
The Molecular Pathology of Hereditary Breast CancerPathobiology, 75
S. Elledge, A. Amon (2002)
The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients.Cancer cell, 1 2
B. Kaufman, R. Shapira-Frommer, R. Schmutzler, M. Audeh, M. Friedlander, J. Balmaña, G. Mitchell, G. Fried, K. Bowen, A. Fielding, S. Domchek (2013)
Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.Journal of Clinical Oncology, 31
A. Antoniou, P. Pharoah, S. Narod, H. Risch, J. Eyfjord, J. Hopper, N. Loman, Hampus Olsson, O. Johannsson, Å. Borg, B. Pasini, P. Radice, S. Manoukian, D. Eccles, N. Tang, E. Oláh, H. Anton-Culver, E. Warner, J. Lubiński, J. Gronwald, B. Górski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjäkoski, O. Kallioniemi, Deborah Thompson, Chris Evans, J. Peto, F. Lalloo, D. Evans, D. Easton (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.American journal of human genetics, 72 5
C. Brekelmans, C. Seynaeve, M. Menke-Pluymers, H. Brüggenwirth, M. Tilanus-Linthorst, C. Bartels, M. Kriege, A. Geel, C. Crepin, J. Blom, H. Meijers-Heijboer, J. Klijn (2006)
Survival and prognostic factors in BRCA1-associated breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 17 3
M. Robson, P. Chappuis, J. Satagopan, N. Wong, J. Boyd, J. Goffin, C. Hudis, D. Roberge, L. Norton, L. Bégin, K. Offit, W. Foulkes (2003)
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentBreast Cancer Research, 6
Xiaoling Xu, Z. Weaver, S. Linke, Cuiling Li, Jessica Gotay, X. Wang, C. Harris, T. Ried, C. Deng (1999)
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.Molecular cell, 3 3
Haijuan Yang, P. Jeffrey, Julie Miller, E. Kinnucan, Yutong Sun, N. Thoma, N. Zheng, Phang-lang Chen, Wen-Hwa Lee, N. Pavletich (2002)
BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.Science, 297 5588
SJ Isakoff, B Overmoyer, NM Tung (2010)
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancerASCO Meet Abstr, 28
A. Veronesi, C. Giacomi, M. Magri, D. Lombardi, M. Zanetti, C. Scuderi, R. Dolcetti, A. Viel, D. Crivellari, E. Bidoli, M. Boiocchi (2005)
Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative casesBMC Cancer, 5
A. Liede, B. Karlan, S. Narod (2004)
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 4
H. Eerola, P. Heikkilä, A. Tamminen, K. Aittomäki, C. Blomqvist, H. Nevanlinna (2005)
Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer familiesBreast Cancer Research, 7
A. Osorio, M. Hoya, R. Rodríguez-López, Á. Martínez‐Ramírez, A. Cazorla, J. Granizo, M. Esteller, C. Rivas, T. Caldés, J. Benítez (2002)
Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancerInternational Journal of Cancer, 99
P. Møller, Å. Borg, D. Evans, N. Haites, M. Reis, H. Vasen, E. Anderson, C. Steel, J. Apold, D. Goudie, A. Howell, F. Lalloo, L. Mæhle, H. Gregory, K. Heimdal (2002)
Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomyInternational Journal of Cancer, 101
L. Carey, E. Winer, G. Viale, D. Cameron, L. Gianni (2010)
Triple-negative breast cancer: disease entity or title of convenience?Nature Reviews Clinical Oncology, 7
T. Huzarski, T. Byrski, J. Gronwald, B. Górski, P. Domagała, C. Cybulski, O. Oszurek, M. Szwiec, K. Gugała, M. Stawicka, Z. Morawiec, T. Mierzwa, H. Janiszewska, E. Kilar, E. Marczyk, B. Kozak‐Klonowska, M. Siołek, D. Surdyka, R. Wiśniowski, M. Posmyk, P. Sun, J. Lubiński, S. Narod (2013)
Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 26
G. Somlo, J. Sparano, T. Cigler, G. Fleming, T. Luu, A. Hurria, J. Mortimer, P. Frankel, H. Chew, R. Nanda, Cynthia Ma, A. Chen, Agustin Garcia, L. Vahdat, D. Gandara, J. Weitzel (2012)
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.Journal of Clinical Oncology, 30
Deborah Thompson, D. Easton (2002)
Cancer Incidence in BRCA1 mutation carriers.Journal of the National Cancer Institute, 94 18
A. Venkitaraman (2009)
Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment.Annual review of pathology, 4
S. Lakhani, M. Vijver, J. Jacquemier, T. Anderson, P. Osin, L. McGuffog, D. Easton (2002)
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 9
M. Kriege, A. Jager, M. Hooning, E. Huijskens, J. Blom, C. Deurzen, M. Bontenbal, J. Collée, M. Menke-Pluijmers, J. Martens, C. Seynaeve (2012)
The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriersCancer, 118
E. Lim, F. Vaillant, Di Wu, N. Forrest, B. Pal, A. Hart, M. Asselin-Labat, D. Gyorki, T. Ward, Audrey Partanen, F. Feleppa, L. Huschtscha, H. Thorne, S. Fox, M. Yan, J. French, Melissa Brown, G. Smyth, J. Visvader, G. Lindeman (2009)
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersNature Medicine, 15
Feng Zhang, Jianglin Ma, Jiaxue Wu, L. Ye, Hong Cai, B. Xia, Xiaochun Yu (2009)
PALB2 Links BRCA1 and BRCA2 in the DNA-Damage ResponseCurrent Biology, 19
M. Greenblatt, P. Chappuis, J. Bond, N. Hamel, W. Foulkes (2001)
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.Cancer research, 61 10
Benjamin Pardo, Belén Gómez-González, A. Aguilera (2009)
DNA Repair in Mammalian CellsCellular and Molecular Life Sciences, 66
G Somlo, JA Sparano, T Cigler (2012)
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium TrialASCO Meet Abstr, 30
N. Turner, J. Reis-Filho, J. Reis-Filho, AM Russell, R. Springall, K. Ryder, D. Steele, K. Savage, C. Gillett, F. Schmitt, A. Ashworth, A. Tutt, A. Tutt (2007)
BRCA1 dysfunction in sporadic basal-like breast cancerOncogene, 26
A. Tutt, D. Bertwistle, Janet Valentine, A. Gabriel, S. Swift, G. Ross, C. Griffin, J. Thacker, A. Ashworth (2001)
Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequencesThe EMBO Journal, 20
L. Saal, Sofia Gruvberger-Saal, C. Persson, Kristina Lövgren, M. Jumppanen, J. Staaf, G. Jönsson, Maira Pires, M. Maurer, K. Holm, Susan Koujak, S. Subramaniyam, J. Vallon-Christersson, H. Olsson, T. Su, L. Memeo, T. Ludwig, S. Ethier, Morten Krogh, M. Szabolcs, V. Murty, J. Isola, H. Hibshoosh, R. Parsons, Å. Borg (2008)
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repairNature Genetics, 40
AR Tan, D Toppmeyer, MN Stein (2011)
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumorsASCO Meet Abstr, 29
L. Cavalli, Baljit Singh, C. Isaacs, R. Dickson, B. Haddad (2004)
Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.Cancer genetics and cytogenetics, 149 1
W. Spannuth, P. Thaker, A. Sood (2007)
Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.American journal of obstetrics and gynecology, 196 4
B Pardo, B Gomez-Gonzalez, A Aguilera (2009)
DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationshipCell Mol Life Sci, 66
G. Rennert, Shantih Bisland-Naggan, O. Barnett-Griness, N. Bar-Joseph, Shiyu Zhang, H. Rennert, S. Narod (2007)
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.The New England journal of medicine, 357 2
R. Kennedy, J. Quinn, P. Mullan, P. Johnston, D. Harkin (2004)
The role of BRCA1 in the cellular response to chemotherapy.Journal of the National Cancer Institute, 96 22
M. El-Tamer, D. Russo, A. Troxel, L. Bernardino, R. Mazziotta, A. Estabrook, B. Ditkoff, F. Schnabel, M. Mansukhani (2004)
Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation CarriersAnnals of Surgical Oncology, 11
E. Honrado, J. Benítez, J. Palacios (2006)
Histopathology of BRCA1- and BRCA2-associated breast cancer.Critical reviews in oncology/hematology, 59 1
B. Leegte, A. Hout, Amie Deffenbaugh, Marian Bakker, Inge Mulder, A. Berge, EP Leenders, J. Wesseling, J. Hullu, N. Hoogerbrugge, M. Ligtenberg, A. Ardern-jones, E. Bancroft, A. Salmon, J. Barwell, Ros Eeles, Jan Oosterwijk (2005)
Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutationsJournal of Medical Genetics, 42
T. Byrski, R. Dent, P. Blecharz, M. Foszczyńska‐Kłoda, J. Gronwald, T. Huzarski, C. Cybulski, E. Marczyk, R. Chrzan, A. Eisen, J. Lubiński, S. Narod (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancerBreast Cancer Research : BCR, 14
B Kaufman, R Shapira-Frommer, RK Schmutzler (2013)
Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II studyASCO Meet Abstr, 31
A. Tan, D. Toppmeyer, M. Stein, R. Moss, M. Gounder, D. Lindquist, J. Ji, A. Chen, M. Egorin, B. Kiesel, J. Beumer, R. DiPaola (2011)
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
A. Monteiro (2003)
BRCA1: the enigma of tissue-specific tumor development.Trends in genetics : TIG, 19 6
H. Eerola, P. Heikkilä, A. Tamminen, K. Aittomäki, C. Blomqvist, H. Nevanlinna (2004)
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer familiesBreast Cancer Research, 7
P. Futreal, Qingyun Liu, D. Shattuck-Eidens, C. Cochran, K. Harshman, S. Tavtigian, L. Bennett, A. Haugen-Strano, J. Swensen, Y. Miki, K. Eddington, M. Mcclure, C. Frye, J. Weaver-Feldhaus, W. Ding, Z. Gholami, P. Söderkvist, L. Terry, S. Jhanwar, A. Berchuck, J. Iglehart, J. Marks, D. Ballinger, J. Barrett, M. Skolnick, M. Skolnick, A. Kamb, R. Wiseman (1994)
BRCA1 mutations in primary breast and ovarian carcinomas.Science, 266 5182
G. Molyneux, M. Smalley (2011)
The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression ProfilingJournal of Mammary Gland Biology and Neoplasia, 16
W. Foulkes (2005)
BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and PrognosisFamilial Cancer, 5
R. Jensen, A. Carreira, S. Kowalczykowski (2010)
Purified human BRCA2 stimulates RAD51-mediated recombinationNature, 467
Bin Wang, S. Matsuoka, B. Ballif, Dong Zhang, A. Smogorzewska, S. Gygi, S. Elledge (2007)
Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage ResponseScience, 316
W. Foulkes, Andrew Shuen (2013)
In Brief: BRCA1 and BRCA2The Journal of Pathology, 230
J. O’Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, C. Rocha, I. Koo, B. Sherman, C. Bradley (2011)
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.The New England journal of medicine, 364 3
Y. Miki, J. Swensen, D. Shattuck-Eidens, P. Futreal, K. Harshman, S. Tavtigian, Qingyun Liu, C. Cochran, L. Bennett, W. Ding, R. Bell, J. Rosenthal, C. Hussey, Thanh Tran, M. Mcclure, C. Frye, T. Hattier, R. Phelps, A. Haugen-Strano, H. Katcher, Kazuko Yakumo, Z. Gholami, Daniel Shaffer, S. Stone, Steven Bayer, Christian Wray, R. Bogden, P. Dayananth, J. Ward, P. Tonin, S. Narod, Pamela Bristow, F. Norris, L. Helvering, P. Morrison, P. Rosteck, Mei Lai, J. Barrett, C. Lewis, S. Neuhausen, L. Cannon-Albright, D. Goldgar, R. Wiseman, A. Kamb, M. Skolnick (1994)
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.Science, 266 5182
A. Tutt, Mark Robson, Judy Garber, S. Domchek, William Audeh, Jeff Weitzel, M. Friedlander, B. Arun, N. Loman, R. Schmutzler, Andrew Wardley, G. Mitchell, H. Earl, M. Wickens, J. Carmichael (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 376
P. Goodwin, K. Phillips, D. West, M. Ennis, J. Hopper, E. John, F. O'Malley, R. Milne, I. Andrulis, M. Friedlander, M. Southey, C. Apicella, G. Giles, T. Longacre (2012)
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 1
E. Levy-Lahad, E. Friedman, E. Friedman (2007)
Cancer risks among BRCA1 and BRCA2 mutation carriersBritish Journal of Cancer, 96
T. Ludwig, D. Chapman, V. Papaioannou, A. Efstratiadis (1997)
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.Genes & development, 11 10
V. Yu, M. Koehler, C. Steinlein, M. Schmid, L. Hanakahi, A. Gool, S. West, A. Venkitaraman (2000)
Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation.Genes & development, 14 11
W. Foulkes, W. Foulkes, P. Chappuis, P. Chappuis, N. Wong, J. Brunet, D. Vesprini, F. Rozen, Z. Yuan, Michael Pollak, G. Kuperstein, S. Narod, L. B´gin (2000)
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.Annals of oncology : official journal of the European Society for Medical Oncology, 11 3
V. Bonadona, Sophie Dussart-Moser, N. Voirin, O. Sinilnikova, H. Mignotte, P. Mathevet, A. Brémond, I. Treilleux, Alain Martin, P. Romestaing, D. Raudrant, R. Rudigoz, G. Lenoir, C. Lasset (2006)
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and reviewBreast Cancer Research and Treatment, 101
Longchuan Chen, Christian Nievera, A. Lee, Xiaohua Wu (2008)
Cell Cycle-dependent Complex Formation of BRCA1·CtIP·MRN Is Important for DNA Double-strand Break Repair*Journal of Biological Chemistry, 283
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
H. Konishi, M. Mohseni, Akina Tamaki, J. Garay, Sarah Croessmann, S. Karnan, Akinobu Ota, Hong Wong, Y. Konishi, B. Karakas, K. Tahir, A. Abukhdeir, J. Gustin, Justin Cidado, Grace Wang, David Cosgrove, R. Cochran, D. Jelovac, M. Higgins, S. Arena, Lauren Hawkins, J. Lauring, A. Gross, C. Heaphy, Y. Hosokawa, E. Gabrielson, A. Meeker, K. Visvanathan, P. Argani, K. Bachman, B. Park (2011)
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cellsProceedings of the National Academy of Sciences, 108
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, R. Dent, J. Lubiński, S. Narod (2010)
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
D. Silver, A. Richardson, A. Eklund, Z. Wang, Z. Szallasi, Qiyuan Li, N. Juul, C. Leong, Diana Calogrias, Ayodele Buraimoh, Aquila Fatima, R. Gelman, P. Ryan, N. Tung, A. Nicolo, S. Ganesan, A. Miron, C. Colín, D. Sgroi, L. Ellisen, E. Winer, J. Garber (2010)
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
L. Carey (2010)
Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
D. Atchley, C. Albarracin, Adriana López, V. Valero, Chris Amos, A. González-Angulo, G. Hortobagyi, B. Arun (2008)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 26
B. Evers, Jos Jonkers (2006)
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospectsOncogene, 25
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
G. Curigliano, A. Goldhirsch (2011)
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.Journal of the National Cancer Institute. Monographs, 2011 43
N. Turner, A. Tutt, A. Ashworth (2004)
Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 4
Rohini Roy, Jarin Chun, S. Powell (2011)
BRCA1 and BRCA2: different roles in a common pathway of genome protectionNature Reviews Cancer, 12
M. Esteller, Jose Silva, G. Domínguez, F. Bonilla, X. Matías-Guiu, E. Lerma, E. Bussaglia, J. Prat, I. Harkes, E. Repasky, E. Gabrielson, M. Schutte, S. Baylin, J. Herman (2000)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.Journal of the National Cancer Institute, 92 7
W. Sikov, D. Berry, C. Perou, Baljit Singh, C. Cirrincione, S. Tolaney, C. Kuzma, T. Pluard, G. Somlo, E. Port, M. Golshan, J. Bellon, D. Collyar, O. Hahn, L. Carey, C. Hudis, E. Winer (2013)
Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)Cancer Research, 73
P. Chalasani, R. Livingston (2013)
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.The oncologist, 18 8
Both BRCA1 and BRCA2 proteins play a role in DNA damage response, and their deficiency leads to chromosomal instability and carcinogenesis. Hereditary mutations in either of these genes increase strikingly the lifetime risk of breast and ovarian cancer and to a lesser extent the risk of males’ breast and prostate cancer and of pancreatic cancer. It is generally accepted that when treated by standard therapy, the prognosis of BRCA- mutated breast cancer patients is equivalent to that of patients with sporadic disease. Increased sensitivity of BRCA-associated breast cancer to DNA damaging chemotherapy, especially platinum compounds, was demonstrated in preclinical models and in clinical trials. However, definitive evidence that would justify their advancement to clinical practice is lacking. Inhibitors of poly (ADP-ribose) polymerase target BRCA-deficient cells specifically. Multiple clinical trials with these compounds are ongoing, although none made its way to clinical practice yet. Hopefully, ongoing clinical research would eventually result in better treatment and improved prognosis.
Current Breast Cancer Reports – Springer Journals
Published: Jul 4, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.